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A BAYESIAN APPROACH TO PREDICT EFFECTIVENESS OF
NEWLY INTRODUCED DRUGS IN DAILY PRACTICE BASED
ON THE RELATION BETWEEN EFFICACY AND
EFFECTIVENESS OF COMPETING INTERVENTIONS
Jansen JP1, Crawford B2
1Mapi Values, Houten,The Netherlands, 2Mapi Values, Boston, MA,
USA
OBJECTIVES: Clinical trials required for licensing are designed
to study efﬁcacy and safety. Information on the effectiveness in
routine practice, which is of interest for cost-effectiveness eval-
uations, is not usually available at the time of launch. As a result,
efﬁcacy data from clinical trials are often used as a proxy for
effectiveness in cost-effectiveness evaluations. However, a differ-
ence between efﬁcacy and effectiveness in the “real world” of
practice can be expected for some drugs, due to patient selec-
tion, non-compliance, and treatment patterns. Therefore, how
the efﬁcacy of a new drug might translate into effectiveness 
in routine practice -both in terms of intermediate and hard 
clinical endpoints- is of primary interest for decision makers.
METHODS: A Bayesian Hierarchical model is introduced by
which simultaneously a meta-analysis of direct and indirect com-
parisons is performed using efﬁcacy and effectiveness data. At
the ﬁrst level of the hierarchical model a parametric model is set
up for each individual efﬁcacy and effectiveness studies; at the
second level a parametric model is constructed to relate the para-
meters from separate efﬁcacy studies to each other, as well as a
model for the effectiveness studies. Intervention speciﬁc differ-
ences between efﬁcacy and effectiveness are related to each other
with a third level. The Bayesian approach can accommodate a
priori beliefs regarding differences for the link between the efﬁ-
cacy and effectiveness across interventions. A particular appeal
of the Bayesian approach lies in the prediction of the effective-
ness of a new intervention, and calculation of the probability
that this intervention is better than the current ones. RESULTS:
The methodology is illustrated with analysis of the efﬁcacy and
effectiveness of statins in terms of LDL reductions and effec-
tiveness regarding cardiovascular endpoints. CONCLUSIONS:
The outlined approach can be used to predict effectiveness of
new drugs awaiting higher quality evidence from randomized
naturalistic trials.
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OBJECTIVES: To develop and validate a scale to measure
patients’ trust in pharmacists for use in future pharmacoeco-
nomic studies METHODS: After literature review to provide ref-
erence for scale development, focus group discussion was then
carried out to assess the relevance of constructs generated and
further explore any new potential domains or items. A candidate
version based on 7-point Likert scale was developed and pilot-
tested for content validity, after which the ﬁnalized version was
tested among eligible Singaporeans across different ethnic and
age groups. Score distributions were assessed for discriminatory
power. Item analyses were done to ensure the corrected item-
total correlation coefﬁcients should be greater than 0.30 for
ﬁnalized items. Exploratory factor analysis was used to deter-
mine dimensionality and suitable homogeneous items. Reliabil-
ity was measured by Cronbach’s alpha to evaluate internal
consistency. Pearson’s correlation coefﬁcients were studied for
construct validity. RESULTS: Altogether 18 items were gener-
ated with good variability (SD > 1.0) and symmetry (means
ranged from -1 to 1) for score distribution. After minor changes
to improve content clarity, ﬁnalized questionnaire was self-
administered among 1196 eligible respondents [mean (SD) age:
38.6 (14.9) years, 51.6% female, 87% >6 years of education].
Six items were dropped due to inadequate item-total correlation
coefﬁcients, leaving 12-item scale for factor analysis. Three
factors (“benevolence”, “technical competence” and “global
trust” of 6, 4 and 4 items respectively) were then identiﬁed
accounting for 55% of the total variance. Cronbach’s alpha was
0.83, indicating high internal consistency. As hypothesized, con-
struct validity was demonstrated by the statistically signiﬁcant
correlations between trust with patient’s satisfaction with phar-
macist’s service (r = 0.54), returning for care (r = 0.30) and 
preference of medical decision-making pattern (r = 0.16). CON-
CLUSIONS: The 12-item trust in pharmacists scale demon-
strated high reliability and construct validity. Further studies
among other populations are suggested to conﬁrm the robust-
ness and even improve the current scale.
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ALLOCATION OF PRESCRIPTION DATA BY INDICATION: A
METHODOLOGY INTEGRATING COMPLEMENTARY PATIENT-
LEVEL INFORMATION SOURCES
Henderson SC, Dockery J
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OBJECTIVES: Many recent FDA approvals have not been for
new chemical entities, but for new indications for drugs already
on the market. This creates new challenges for pharmaceutical
companies and health plans to monitor use by indication in a
timely manner, which may be necessary for monitoring compli-
ance and disease management programs or managing prescrip-
tion beneﬁts by indication. Health plan claims data have the
ability to link prescriptions to indication but typically suffer from
a time lag. Longitudinal prescription data are available closer 
to real-time, but do not include indication. METHODS: We
describe a modeling approach to parse out different indications
for a product using a combination of health plan claims data and
longitudinal prescription data. We explain how predictive
models are developed, tested and validated, using these different
data sources. Logistic models are developed using information
from health plan claims data, representing the most robust
source of medical and pharmacy claims linked at a de-identiﬁed
patient level. Since the comprehensive health plan-sourced claims
data may not be robust or timely enough for some applications,
the data are used to develop a model that can be applied to more
timely and robust longitudinal prescription information.
RESULTS: The approach involves determination of appropriate
diagnoses and drugs, construction of training and holdout data
sets, development of logistic regression models, and evaluation
of model performance. Electronic claims data could be used to
provide diagnosis information, but patients’ claims may be
missing, leading to gaps and inconsistencies in diagnosis-level
reporting, causing the predictive models to be less robust and
resulting in erroneous parsing of prescriptions by disease. CON-
CLUSIONS: The approach we propose is it makes the best use
of disparate patient-level data sources, such as plan-based inte-
grated claims data and pharmacy-based longitudinal prescription
data to produce a robust and timely parsing of indication.
